AMFR

Across TCGA pan-cancer cohorts, AMFR mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AMFR data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher AMFR mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AMFR expression acts as an unfavorable survival marker, although some lineages such as GBM and COAD show a favorable association.

GBM, COAD, and HNSC are the cancer types where AMFR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.444	0.209	.001	15	view →
COAD	DFS	Median	All	1.000	0.774	.049	6	view →
HNSC	DFS	Quartile	III,IV	1.000	0.324	.024	6	view →
UCEC	DFS	Median	All	0.932	1.000	.022	4	view →
LUAD	DFS	Tertile	All	0.650	1.000	.009	2	view →
LSCC	DFS	Median	II,III,IV	0.451	0.877	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AMFR–GBM (DFS)

Open the GBM breakdown →